Front Page
Skip to content
Monte Carlo, Monaco

News & Perspective

MonteCarloTimes.com

MonteCarloTimes.com Front Page · Article Archive

Science ·

UK confirms plans to update gene-therapy definitions while retaining approval standards

The November 19 confirmation follows consultation and still requires notification procedures and parliamentary approval.

Monte Carlo Times · News Desk

The UK government confirmed plans November 19 to update the legal definition of gene therapy medicinal products. The intended change would place certain synthetic gene therapies and newer genome-editing treatments within the established advanced-therapy regulatory framework.

The proposals received support from 83% of respondents to a consultation led by the Medicines and Healthcare products Regulatory Agency and the Department of Health in Northern Ireland. They would amend the Human Medicines Regulations 2012, subject to international notification procedures and approval by Parliament. The confirmation sets out a proposed classification change, rather than an approval for any individual treatment.

The government says existing processes and standards for medicine safety, quality and efficacy will remain unchanged. Already licensed medicines would not need reclassification. The aim is to make the applicable requirements clearer for developers using synthetic genetic material and genome-editing technologies. The official November 19 release also places the announcement in the context of the DIA-MHRA summit held in London on November 16–17.